Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system in adults. 1 Epidermal growth factor receptor (EGFR) variant III (vIII) is the most common mutant EGFR found in GBM and is known to be associated with aggressive pathological features such as enhanced tumorigenicity, invasion, and therapeutic resistance. [2] [3] [4] This constitutively active mutant of EGFR is generated through deletions encompassing exons 2-7, which result in a transcript producing a truncated receptor. 5 EGFRvIII in GBM resides primarily on extrachromosomal DNA (ecDNA) in an amplified manner. 6, 7 One study investigating EGFRvIII breakpoints 
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NeuroOncology suggests that Alu (Arthrobacter luteus) repeat elements may play a role in genomic rearrangements leading to the origin of the mutant. 8 However, a link between underlying mechanisms of EGFR gene amplification and genomic rearrangements that result in a vIII deletion is not yet well understood.
The proximal genomic breakpoints of EGFRvIII can occur anywhere within a 123-kb first intron, which presents a significant challenge for polymerase chain reaction (PCR)-based mapping. 8, 9 Next-generation sequencing is a method to map these deletions but has yet to be routinely applied in the clinic. 10 Additionally, although reliable antibodies that can distinguish wild-type EGFR from EGFRvIII on tissue sections exist, 11 the presence of amplified and rearranged genes does not always correlate with their expression due to epigenetic regulation. 12 In an effort to provide a more efficient approach for analyzing EGFRvIIIpositive GBMs, we modified previously reported mapping techniques 8, 9 by first screening samples for possible EGFRvIII deletions using genomic quantitative (q)PCR and then direct mapping of these deletions through arrayed PCR. The breakpoint sequence analyses suggest distinct DNA repair processes as biogenic mechanisms.
Materials and Methods

Samples
Twenty-nine GBM tumor samples from 29 patients who underwent surgery at the University of California San Diego were analyzed. Paired plasma samples were obtained from all the patients. In one patient (BC010), who did not show any clear evidence of leptomeningeal disease, the cerebrospinal fluid (CSF) was collected through a puncture of the lateral ventricle before resection of the tumor. All samples were collected with informed consent according to the appropriate protocols approved by the institutional review board. Six GBM neurosphere cell lines and one GBM tissue that were analyzed in our previous studies 7, 9 and known to have EGFRvIII were included in the breakpoint sequence analysis.
DNA Extraction
Tumor DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer's instructions.
Cell-free DNA (cfDNA) from plasma and CSF was extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen). The obtained cfDNA was unbiasedly amplified according to a previous report. 13 Briefly, 5 ng of cfDNA was blunted and ligated using T4 DNA polymerase and T4 DNA ligase (New England Biolabs), respectively. Then, the elongated or circularized DNA was amplified via random primer-initiated multiple displacement amplification using the Illustra GenomiPhi HY DNA Amplification Kit (GE Healthcare Life Sciences). The amplified DNA was purified by ethanol precipitation and quantified using Qubit dsDNA HS (Thermo Fisher Scientific).
Extracellular vesicles from plasma or CSF were purified using ExoQuick (System Biosciences) according to the manufacturer's instruction. DNA was further extracted from extracellular vesicles using the DNeasy Blood and Tissue Kit (Qiagen) and then a portion of the DNA was treated with heparinase I (Sigma-Aldrich) according to a previous report.
14 Briefly, 5 µL of DNA sample was combined with 5 µL of heparinase working solution (0.085 IU/mL of heparinase I, 10 mmol/L Tris HCl pH 7.5, 2 mmol/L CaCl 2 , 25 mmol/L NaCl) and incubated at 25°C for 3 h. Extracellular-vesicle DNA (evDNA) with and without heparinase I treatment was then blunted, ligated, amplified, and purified in the same manner as cfDNA.
Quantitative PCR and Statistical Analyses
Triplicate qPCR reactions containing 10 ng of DNA were run on a CFX96 Real Time System (Bio-Rad) with the following reaction conditions: 95°C for 5 min, 40 cycles of 95°C for 15 s and 58°C for 30 s. Three primer pairs between exons 2 and 7 were designed to quantify nonvIII EGFR and 2 pairs were set outside for the quantification of both vIII and non-vIII EGFR (Fig. 1A) . The data were normalized to human hemoglobin beta (HBB) in each sample and again normalized to human genomic DNA (Promega), and the relative copy number of each region was determined using the 2-ΔΔCt formula. Primer sequences are listed in Supplementary Table S1 . EGFR
Importance of the study
EGFRvIII is a truncation mutant lacking exons 2-7 and is associated with glioblastoma aggressiveness. The breakpoints of this large genomic deletion are generated by unknown mechanisms, are highly variable between patient samples, and are difficult to map. Here we show a sensitive and specific method for determining EGFRvIII-positive samples using discriminatory quantitative PCR followed by specific breakpoint mapping using arrayed primers spanning the long intron 1 of EGFR. Patient-specific PCR, designed based on the mapping results, is useful for the detection of EGFRvIII breakpoints unique to each tumor and we show a case where patient-specific breakpoint products were detected in the CSF using this method. Detailed breakpoint sequence analyses show traces of different types of genomic rearrangements and DNA repair mechanisms. Analyses of SNPs suggest that different deletions may evolve from precursor amplified non-vIII EGFR. 
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was regarded as amplified when the average of the relative copy numbers of the 2 regions outside the deletion compared with HBB was 2 or more. Datasets were analyzed by unpaired Student's t-test using GraphPad Prism software.
Mapping of EGFRvIII
A forward primer within exon 1 (e1f) and 45 forward primers within intron 1 (i1.1-i1.45) were designed to be spaced approximately 2.7-kb apart from neighboring primers. Together with forward primers in exons 7 and 8 (e7f and e8f) as DNA quality controls, all 48 forward primers were combined with an anchor primer in exon 8 (e8r) and PCR was performed on 100 ng of genomic DNA from tumor samples (Fig. 1C) . Primer sequences are listed in Supplementary  Table S2 . PCR was performed using Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher Scientific) in 10-μL reaction volume containing 0.2 μM of each primer with the following reaction conditions: 94°C for 2 min, 40 cycles of 94°C for 15 s, 59°C for 30 s, and 68°C for 15 min.
PCR amplicons obtained from the mapping PCR were ligated into the pCR4-TOPO vector using the TOPO TA Cloning Kit (Life Technologies) and sequenced at Retrogen (San Diego, California) using M13 forward (−20) (5ʹ-GTAAAACGACGGCCAG-3ʹ) and M13 reverse (5ʹ-CAGGAAACAGCTATGAC-3ʹ) primers. Obtained sequences were aligned to the EGFR gene using the University of California Santa Cruz Genome Browser (GRCh38/hg38 assembly).
Detection of Patient-Specific EGFRvIII in Different Samples
Patient-specific primers flanking the EGFRvIII breakpoints mapped in each patient were designed. The primer sequences and the annealing temperature for each primer set are listed in Supplementary Table S3 . PCR was performed on tumor DNA, cfDNA from plasma and CSF, and DNA from extracellular vesicles in plasma using Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher Scientific) in 10-μL reaction volume containing 0.2 μM of each primer with the following reaction conditions: 94°C for 2 min, 40 cycles of 94°C for 15 s, each different annealing temperature for 30 s, and 68°C for 30 s.
Whole Genome Sequencing Analyses
Paired-end next-generation sequencing was performed for all the tumor samples on an Illumina Hi-Seq with 150 cycles at Novogene (Chula Vista, California). Sequence reads were then mapped to the GRCh38/hg38 genome using bwa-mem (https://arxiv.org/abs/1303.3997v2). Next, canonical alignment information was extracted from reads flagged with SA tags, which mark chimeric alignments (http://samtools. github.io/hts-specs/SAMtags.pdf). Genomic rearrangements were then predicted when multiple canonical alignments shared the same breakpoint coordinates. Based on alignments, breakpoints involving the EGFR locus were extracted and classified as EGFRvIII deletions if breaks spanned intron 1 and exon 7 or intron 7. The breakpoint sequences were obtained for 7 samples from our previous study 7 in the same manner. The proportion of each EGFRvIII deletion among total EGFR copies was calculated based on the number of unique reads containing those junctions compared with the total number of unique reads mapped to the breakpoints, with or without chimeric alignments.
Using the canonical alignment information extracted as above, interchromosomal and intrachromosomal rearrangements were analyzed. Breakpoints observed in more than 25 reads were plotted using Circos software (http://circos. ca/software/).
Single Nucleotide Polymorphism Assays
Total RNA was extracted from the tumor samples using the RNeasy Plus Mini Kit (Qiagen) and was reverse transcribed using RNA to cDNA EcoDry Premix (Clontech) according to the manufacturer's instruction. RNA and cDNA were obtained from a glioma sphere cell line, GBM 39, which is known to have ecDNA harboring homogeneous amplicons of EGFRvIII, and was included in the analysis as a control. PCR was performed for the obtained cDNA using a forward primer within exon 1 and reverse primers within exons 15, 16, 20, and 25. The sequences of the primers were: exon 1 forward, 5ʹ-GGCTCTGGAGGAAAAGAAAG; exon 15 reverse, 5ʹ-GCAGTTTGGATGGCACAGGTG-3ʹ; exon 16 reverse, 5ʹ-TTCGTTGGACAGCCTTCAAG-3ʹ; exon 20 reverse, 5ʹ-GGCATGAGCTGCGTGATG-3ʹ; and exon 25 reverse, 5ʹ-TGCTGAAGAAGCCCTGCTGTG-3ʹ. Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher Scientific) was used and the reaction conditions were as follows: 94°C for 2 min, 35 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 3 min. Single nucleotide polymorphism (SNP) sites rs2227983, rs17290169, s2227984, and rs1050171 in exons 13, 15, 16, and 20, respectively, of EGFR in the PCR amplicons derived from non-vIII EGFR and EGFRvIII were sequenced separately using 3 different primers: 5ʹ-TGTTTGGGACCTCCGGTCAG-3ʹ; 5ʹ-TGCCTCAGGCCATGAACATC-3ʹ; and 5ʹ-AGAAGCAACATC TCCGAAAG-3ʹ. These SNP sites were compared with sequence of DNA obtained from matched patients' plasma.
Results
Screening and Mapping of EGFRvIII Breakpoints in Tumor Samples
We analyzed 29 GBM specimens by genomic qPCR and found amplification (2.4-to 190-fold, average 50-fold) in 11 of these samples (38%; Fig. 1B ). To identify EGFRvIII rearrangements, copy numbers of the 3 regions deleted in EGFRvIII were compared with those of the regions maintained in EGFRvIII. If any of the latter PCR amplicons yielded copy numbers significantly greater (P < 0.05) than any of the former ones, these samples were regarded as possibly containing EGFRvIII deletions. Eight of 29 samples displayed such differences (Fig. 1B) .
We then applied the arrayed PCR to the above 8 samples. Six of the 8 samples showed a stepwise pattern of PCR amplicons with approximately 2.7-kb incremental differences based on the spacing of neighboring primers (Fig. 1D) . Two samples (BC010t and BC034t) harbored 2 different sets of these serial PCR amplicons. One set of the PCR amplicons was observed in 4 samples (BC039t, BC048t, BC051t, and BC083t), while amplicons were not obtained from 4 other samples (Fig. 1D) . A forward primer that was designed to yield amplicons regardless of existence of EGFRvIII, e8f, yielded amplicons in all samples (Fig. 1D) . In summary, 8 different EGFRvIII breakpoints in 6 samples were detected.
All samples were subjected to whole genome sequencing (WGS) in parallel to validate the results derived from PCR-based mapping. All EGFRvIII breakpoints mapped by PCR were confirmed by WGS; no additional EGFRvIII breakpoints were identified by WGS (Supplementary  Table S4 ). Thus, the sensitivity and specificity of our mapping procedure, as validated by WGS, were both 100% in detecting EGFRvIII, and by qPCR screening were 100% and 91%, respectively. The frequencies of the reads derived from each EGFRvIII breakpoint among all the reads from EGFR in each patient were 4.6%-76% (Supplementary  Table S4 ). Additionally, WGS identified other EGFR rearrangements in these 29 samples, including a tandem duplication of chr7:55,173,011-55,173,064, which resulted in an in-frame 18 amino acid insertion in exon 17 (BC003t), and another case with EGFRvII(BC048t), a deletion encompassing exons 14 and 15 15 (Supplementary Table S4 ).
Detection of Patient-Specific EGFRvIII in Different Samples
Primers designed for each specific sample generated amplicons of the expected size only in each corresponding tumor sample ( Fig. 2A) . To determine if such patientspecific EGFRvIII breakpoints could be detected in matched plasma and thus be used as a "liquid biopsy" platform, 16 EGFRvIII breakpoint PCR was performed using cfDNA 17 or evDNA 18, 19 from plasma from 4 of the patients whose tumors were EGFRvIII positive (BC010, BC034, BC048, and BC083). Patient-specific EGFRvIII-derived PCR amplicons were not detected in 100 ng heparinase I treated or untreated plasma cfDNA or evDNA (Fig. 2B, C) . However, patient-specific EGFRvIII amplicons were detected in cfDNA isolated from matched CSF (Fig. 2D) .
Detailed Breakpoint Analysis Reveals Different Genomic Rearrangements
Among 15 EGFRvIII breakpoints in this analysis, 4 (BC010t-1, BC010t-2, BC034t-1, and GBM 6) had small insertions of up to 3 nucleotides (Fig. 3A, B) . In one sample (HK359), an insertion of an approximately 42-kb sequence from outside of the EGFR locus was detected (Fig. 3A) . Insertions of a duplicated 27-nucleotide sequence and a 72-nucleotide inverted sequence at breakpoint junctions accompanied by 6-nucleotide microhomologies were observed in BC010t-1 and BC039t, respectively (Fig. 3A, B) . Nine breakpoint junctions (BC034t-2, BC048t, BC051t, BC083t, GBM 39, HK296, HK301, HK423, and UCSD002.26) were simple deletions without insertion (Fig. 3A, B) . Among those 9 breakpoints, 3 (BC034t-2, BC083t, and HK296) showed microhomologies of 2 to 3 nucleotides at the junctions (Fig. 3B) .
Complex Chromosomal Rearrangements Observed in Tumor Samples
Twelve samples had chromosomal rearrangements involving chromosome 7 (Fig. 4A ). Ten out of 11 samples with EGFR amplification and all of the EGFRvIII-positive samples showed some rearrangements involving chromosome 7, while there was no EGFR amplification in 16 of 17 samples that did not show any chromosome 7 rearrangements (Fig. 4B) . One sample with EGFR amplification without chromosome 7 rearrangements (BC068) had the lowest relative copy number of EGFR (2.4), suggesting either that there was no actual EGFR focal amplification or that chromosomal rearrangements were not detected due to a small fraction of the cells with EGFR amplification in this specimen.
SNP Analysis Indicates EGFRvIII Is Derived from Amplified Non-vIII EGFR
RNA from 2 patient samples (BC010t and BC034t) that had 2 different breakpoints (Fig. 1D ) was further analyzed to identify which allele the EGFRvIII was derived from. Two different-sized amplicons from non-vIII EGFR and EGFRvIII were obtained by reverse transcription PCR with a forward primer in exon 1 and a reverse primer in exon 20 in the tumors (Fig. 5A ). Plasma DNA from these patients showed nucleotide differences between 2 alleles at 2 SNP sites (rs2227983 and rs2227984) (Fig. 5B, C) ; however, these sites in cDNA derived from nonvIII EGFR, and EGFRvIII showed homogeneous nucleotide compositions in both patients (Fig. 5B, C) . Assuming the cDNA from non-amplified or the normal allele of EGFR is undetectable by sequencing due to being overwhelmed by amplified non-vIII EGFR in these samples (Fig. 1B) , these results suggest that EGFRvIII, with 2 different breakpoints in each patient, was derived from amplified full-length EGFR, as both species of EGFR shared the same allele-determining SNP.
Discussion
Here we present simplified methods to screen tumor samples for the presence of EGFR amplification and EGFRvIII. The screening by qPCR targeting several loci in EGFR was sensitive and specific to detect EGFRvIII. Though the specificity was 91% in our analysis of 29 tumor samples, if the analysis was limited to only samples with EGFR amplification, with an assumption that EGFRvIII is exclusively associated with amplification of the gene, 20 our specificity reached 100%. In our analysis, 11 of 29 samples (38%) had EGFR amplification, and 6 (55%) of those with the amplification had EGFRvIII, which is consistent with previous reports. 20, 21 Although EGFRvIII-targeted therapeutics have not yet proven to be efficacious through phase III clinical trials for GBM patients, 22 and therefore clinical relevance of detecting EGFRvIII is limited for now, our method would be a rapid and sensitive way to detect EGFRvIII in tumor DNA and would have potential for diagnostic application if therapeutic challenges, such as drug delivery and intrinsic resistance of tumor cells, are overcome in the future. 23 Mapping of EGFRvIII has been performed with similar approaches as described here, although the sensitivity and
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specificity of these methods have not been evaluated. 8, 9 In our experience from a previous study, 9 it is often difficult to distinguish specific EGFRvIII breakpoint amplicons from nonspecific PCR products. Thus, using a large number of intron 1 primers spaced equidistant from each other, our goal was to reduce the risk of a false negative result and to distinguish specific and nonspecific amplicons easily by determining if a stepwise pattern of PCR amplicons derived from BC010  BC034  BC048  BC083  BC010  BC034  BC048  BC083  BC010  BC034  BC048  BC083  BC010  BC034  BC048  BC083  BC010  BC034  BC048  BC083  BC010  BC034  BC048  BC083  BC010  BC034  BC048  BC083   96bp  96bp  96bp   96bp  96bp  96bp  75bp  128bp  85bp  114bp  90bp  112bp  96bp   112bp  75bp  128bp  85bp  114bp  96bp Primer 
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the placement of neighboring primers is present. Indeed, our mapping method combined with the qPCR screening in the current study had 100% sensitivity and specificity for detecting EGFRvIII breakpoints that were found by WGS analysis. The sensitivity for detection of EGFRvIII breakpoints by this PCR approach was high enough to detect a rare population of EGFRvIII, as in the case of BC010t-2, which accounted for only 4.6% of total EGFR reads in WGS. As for the locations of the breakpoints, a previous report suggesting involvement of Alu repeat sequences in EGFRvIII rearrangement shows that all the intron 7 breakpoints are located in or downstream of the intron 7 Alu sequence. 8 On the other hand, some of the samples analyzed in the current study and in our previous work 9 had intron 7 breakpoints upstream of this region, suggesting involvement of other mechanisms. In one tumor (BC010t-1), we detected the 3ʹ EGFRvIII breakpoint in the middle of exon 7. In this case, it was assumed that the deletion of the splice acceptor site in intron 6 probably resulted in skipping of exon 7 during splicing, thus generating EGFRvIII. In terms of intratumoral heterogeneity, there were 2 cases with 2 different EGFRvIII breakpoints, which is in agreement with previous studies showing breakpoint heterogeneity within a single tumor. 24, 25 Assuming that these 2 different breakpoints were derived from separate regions from the same tumor, this raises the possibility that further varieties of EGFRvIII break structures exist in other portions of a large tumor mass. Furthermore, discrepancy between the results of tumor DNA and RNA in those patients whose RNA data were available from our previous study 26 (Supplementary Table S5 from sampling bias of the tumors where EGFRvIII-positive regions are scattered within each tumor as described previously. 25 Considering such heterogeneity within each tumor, multiple sampling of tumor regions coupled with comprehensive immunohistochemistry and DNA and RNA analyses for EGFRvIII would be necessary for informative diagnostic information.
Our mapping results enabled patient-specific PCR that yielded EGFRvIII-derived PCR amplicons specific to each patient's tumor, and for a single case where a CSF sample was available, this approach detected the same patientspecific amplicon from cfDNA. Diagnosis using cfDNA from liquid biopsies, as a surrogate for tissue biopsy, has been used for cancer patients to monitor treatment responses and tumor relapses. 16 In the setting of a brain tumor, cfDNA is difficult to detect in plasma DNA due to the blood-brain barrier, 27 which is consistent with our results where EGFRvIIIderived PCR amplicons were not obtained from either cfDNA or evDNA derived from plasma, even with modifications to enhance sensitivity, such as preamplification 13 and heparinase I treatment. 14 In contrast, a previous study analyzing patients with brain tumors, including 8 GBMs, shows that tumor DNA was detectable in CSF, 28 as in one of the cases in the current study, suggesting that this source of cfDNA provides a means to detect EGFRvIII mutations based on a tumor-defined, patient-specific breakpoint fingerprint.
Several approaches for liquid biopsy of GBM have been attempted. 29 These include detection of EGFRvIII in evRNA in plasma and CSF, with detection sensitivity ranging from 36% to 61%. 26, 30, 31 The benefit of a DNA assay would be that it could track EGFRvIII breakpoints specific to each tumor, as each breakpoint presents a unique junctional fingerprint. In contrast, an RNA analysis cannot discriminate different populations of EGFRvIII with different genomic breakpoints, since the junction sequence between exons 1 and 8 in EGFRvIII RNA is constant among different samples. On the other hand, the commonality in RNA breakpoints might enable the detection of EGFRvIII in evRNA from plasma. 31 Although there was only one patient for whom both results of plasma cfDNA in the current study and evRNA from our previous study 26 were available (Supplementary Table S5 ) and further studies to compare the sensitivity of DNA and RNA detection in biofluid are necessary, we expect that the approach of screening and mapping genomic EGFRvIII breakpoints presented here could be integrated with other diagnostic tools in the future. Furthermore, with the advent of CRISPR/Cas9 gene-editing technology, mapped EGFRvIII junctions could serve as loci for insertion of a suicide gene, such as herpes simplex virus thymidine kinase. 32 Such an approach could be a highly specific method to target EGFRvIII-positive tumor cells for which the breakpoints were accurately mapped.
By sequencing EGFRvIII breakpoints, we found different types of rearrangements and some with sequences inserted between intron 1 and exon 7 or intron 7 sequences. Such insertions could be large, as in HK 359, where there was an insertion of approximately 42 kb. This insertion scenario would be impossible to detect using 
our mapping PCR strategy due to length of the inserted sequence. Our mapping PCR would be able to generate amplicons at the breakpoints with relatively short insertions, presumably up to a few kilobases. Thus, the size of an insertion is one of the limitations encountered with our mapping method. Twelve of the 15 breakpoints (80%) analyzed had either short insertions up to 3 nucleotides or simple deletions of intron 1 to exon 7 sequences, suggestive of non-homologous end joining (NHEJ) as a mechanism for repair. 33 Three (20%) showed microhomology of 2 to 3 nucleotides between their original upstream and downstream sequences, suggestive of NHEJ or microhomology-mediated end joining based on the length of the homologies. 34, 35 A duplication or an inversion found in another 2 cases (13%), accompanied by microhomologies, may suggest involvement of replication mechanisms such as fork stalling and template switching or microhomologymediated break-induced replication 36, 37 (Fig. 3B) . Together, these varieties of repair mechanisms play a role in the biogenesis of EGFRvIII rearrangement.
One of the EGFR-amplified samples was accompanied by extensive rearrangement of chromosome 7 (BC020), suggesting potential involvement of chromothripsis, 38, 39 which is associated with generation of double minutes or ecDNA, [39] [40] [41] where amplified oncogenes in cancer cells, including EGFR in GBM, mostly reside. 7, 42 All 6 cases with EGFRvIII in our analysis had amplification of both EGFRvIII and non-vIII EGFR and these amplicons are likely to be localized to ecDNA. 7 It has been previously reported that ecDNA is prone to acquire additional mutations, probably due to its localization in micronuclei. 43, 44 The commonality in the alleles of origin of all EGFRvIII and amplified non-vIII EGFR may suggest that EGFRvIII is derived through further rearrangements of amplified full-length EGFR on ecDNA, which is also supported by previous studies. 24, 25 In conclusion, detailed analyses of EGFRvIII deletions efficiently detected by our PCR approach gives us implications as to how this aggressive mutant arises in GBM. We expect such findings will lead to a better understanding of how clonal evolution and the heterogeneity observed in GBM 25, 45, 46 arise.
